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Apnoea of prematurity (AOP) is a complete cessation 
of breathing that occurs as a result of immaturity 
of respiratory control in preterm infants and is 
considered a physiological rather than pathological 
process. It is most commonly defined as a pause in 
breathing that lasts more than 15 seconds or one that is associated 
with desaturation and bradycardia.[1]
AOP remains among the most commonly diagnosed conditions in 
the newborn intensive care unit.[2,3] The incidence of AOP is inversely 
correlated with gestational age (GA). In infants who are born at <29 
weeks’ gestation, AOP is almost universal, while at 35 weeks only 7% 
of infants will have AOP.[1]
Treatment modalities for AOP include continuous positive-pressure 
ventilation and methylxanthines. The two methylxanthines most 
commonly used are caffeine and theophylline (and aminophylline, the 
intravenous form of theophylline).[4] Cochrane meta-analysis has shown 
that there is a significant reduction in apnoeic episodes and subsequent 
mechanical ventilation in infants treated with methylxanthines.[5]
Although theophylline is effective, caffeine has been shown to be 
the faster-acting and safer of the two drugs, with a wider therapeutic 
range and fewer side-effects. It also has a longer half-life (up to 100 
hours) and so requires only once-daily dosing.[6,7]
Schmidt et al.[8,9] showed a significant reduction in the rate 
of bronchopulmonary dysplasia and an improvement in 
neurodevelopmental outcome at 18 - 21 months in infants treated 
with caffeine.[8,9] However, this neurodevelopmental advantage could 
not be demonstrated at 5 years of age.[10]
As a result of its proven benefits and cost-effectiveness, caffeine 
is now one of the most widely used drugs in neonatology.[11] Despite 
being on the World Health Organization Essential Drugs List for 
children, it is unavailable in many low-resourced settings owing to 
cost and manufacturing problems.[4]
Although caffeine prophylaxis as opposed to treatment has not 
been definitively proven to be effective,[5] many units give prophylaxis 
to infants who have the highest risk of apnoea.[12] Caffeine is generally 
stopped at 33 - 35 weeks’ postmenstrual age.[8,12]
Objective
To ascertain whether the caffeine protocol based on international 
guidelines is applicable in our setting.
Methods 
Groote Schuur Hospital is a tertiary referral hospital in Cape Town, 
South Africa. The neonatal unit treats over 500 very-low-birth-weight 
infants (<1 500 g) per year. Owing to socio-economic circumstances, 
very few of the mothers have had early ultrasound scans and the GA 
of the babies is usually estimated using the modified Ballard Score.[14]
The Groote Schuur nursery caffeine protocol was developed 
using international guidelines. Since our high patient-to-nurse ratio 
results in some apnoeas not being detected, it was decided to start all 
infants of <35 weeks’ GA at birth on caffeine prophylactically. The 
protocol states that the caffeine dose should be adjusted for weight 
and discontinued when the corrected GA is 35 weeks, provided there 
have been no apnoeic episodes in the previous week. Caffeine base is 
the solution used in our nursery, and after a loading dose of 10 mg/
kg, a daily dose of 5 mg/kg is used.
In a prospective folder review done over the months of December 
2011 and January 2012, we reviewed the folders of all premature 
babies discharged from the nursery. Information was obtained from 
the infant records and medication charts and recorded on a structured 
data pro forma. Data collected included GA at birth and how this was 
ascertained, caffeine prescriptions, reasons for caffeine discontinuation, 
and apnoeic events. Permission for the study was obtained from the 
Faculty of Health Sciences Research Ethics Committee.
Results
Fifty-five babies fulfilled our inclusion criteria. All babies born at 
<35 weeks’ gestation were started on caffeine as per protocol. Two 
patients who were scored at 36 weeks were also started on caffeine. 
One of these was given caffeine as treatment for apnoea, while the 
other was given caffeine in error. GA was assigned in 47 (85.5%) of 
the babies using the modified Ballard Score and in 8 (14.5%) from 
ultrasound findings.
Background. Methylxanthines such as caffeine have been proven to reduce apnoea of prematurity and are often discontinued at 35 weeks’ 
corrected gestational age (GA).
Objective. To ascertain whether a caffeine protocol based on international guidelines is applicable in our setting, where GA is often uncertain.
Methods. A prospective folder review was undertaken of all premature infants discharged home over a 2-month period.
Results. Fifty-five babies were included. All babies born at less than 35 weeks’ GA were correctly started on caffeine as per protocol. GA was assigned 
in 85.5% of cases by Ballard scoring and in 14.5% from antenatal ultrasound findings. Caffeine was discontinued before 35 weeks in 54.5%.
Discussion. The main reason for discontinuing caffeine early was the baby’s ability to feed satisfactorily, a demonstration of physiological 
maturity. As feeding behaviours mature significantly between 33 and 36 weeks, the ability to feed may be a good indication that caffeine 
therapy can be stopped.
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We found that nearly 60% of the infants 
receiving caff eine in our unit did not have 
their doses increased as they gained weight. 
In only 18 out of the 55 patients (32.7%) was 
caff eine discontinued at 35 weeks’ corrected 
GA as per protocol. In the majority of the 
babies (54.5%), caff eine was discontinued 
earlier than the guidelines recommended 
(Fig. 1).
The main reason (60.0%) given for stopping 
caffeine early was that the babies were cup 
feeding or breastfeeding and therefore getting 
ready to go home or into kangaroo mother 
care (Fig. 2). Continuing to give caffeine after 
35 weeks (12.7% of babies) was either due to 
concerns about ongoing apnoea or failure to 
stop the medication according to protocol.
There were no recorded apnoea events 
after caffeine was stopped.
Discussion
Th e study revealed that the caff eine dose 
was not appropriately adjusted as the weight 
increased in the majority of babies (60%). 
Th is fi nding highlights the need for vigilance 
in reviewing dosages of not only caff eine but 
all long-term medications where the dosage 
is based on weight.
In 55% of the babies, caffeine was stopped 
at a lower GA than recommended by the 
protocol. This was due to their imminent 
discharge, as they showed signs of 
physiological maturity such as the ability to 
feed satisfactorily. As we do not discharge 
babies on caffeine, it is usually discontinued 
at least 5 days before discharge. Studies have 
shown that feeding behaviour in premature 
infants matures significantly between 33 and 
36 weeks after conception, and swallowing 
infrequently interrupts respiration during 
feeding after 35 weeks after conception. 
Babies who are unwell or have respiratory or 
neurological complications may have a delay 
in developing the ability to feed.[13]
Ballard scoring can misjudge GA by 
up to 2 weeks even when the scorer is 
experienced.[14] Less experienced doctors 
have even greater margins of error. Also, 
many of our babies are growth restricted,[15] 
which often confounds GA scoring as 
smaller babies may be scored as younger.[16]
Reassuringly, no babies who had their 
caffeine stopped because they were able to 
feed subsequently developed apnoea.
Conclusion
In our setting, GA is oft en diffi  cult to 
estimate and the potential margin of 
error is wide. Ability to feed rather than 
the estimated GA may therefore be the 
better indicator to stop administration of 
caff eine or other methylxanthines. Stopping 
methylxanthines based on feeding could 
result in less unnecessary therapy and even 
shorten hospital stay.
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Fig. 2. Reasons for discontinuing caff eine before 35 weeks.
Fig. 1. Corrected gestational ages when caff eine was discontinued.
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